These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 4016708)

  • 1. Do regular ovulatory cycles increase breast cancer risk?
    Henderson BE; Ross RK; Judd HL; Krailo MD; Pike MC
    Cancer; 1985 Sep; 56(5):1206-8. PubMed ID: 4016708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevention of breast cancer through reduced ovarian steroid exposure.
    Spicer DV; Pike MC
    Acta Oncol; 1992; 31(2):167-74. PubMed ID: 1622631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospects for the primary prevention of breast cancer.
    Bernstein L; Ross RK; Henderson BE
    Am J Epidemiol; 1992 Jan; 135(2):142-52. PubMed ID: 1311141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
    Katkam RR; Gopalkrishnan K; Chwalisz K; Schillinger E; Puri CP
    Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical estradiol secretion and ovulation patterns caused by luteal out-of-phase (LOOP) events underlying irregular ovulatory menstrual cycles in the menopausal transition.
    Hale GE; Hughes CL; Burger HG; Robertson DM; Fraser IS
    Menopause; 2009; 16(1):50-9. PubMed ID: 18978637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of physical activity and breast cancer.
    Friedenreich CM; Rohan TE
    Epidemiology; 1995 May; 6(3):311-7. PubMed ID: 7619942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progesterone from ovulatory menstrual cycles is an important cause of breast cancer.
    Coelingh Bennink HJT; Schultz IJ; Schmidt M; Jordan VC; Briggs P; Egberts JFM; Gemzell-Danielsson K; Kiesel L; Kluivers K; Krijgh J; Simoncini T; Stanczyk FZ; Langer RD
    Breast Cancer Res; 2023 May; 25(1):60. PubMed ID: 37254150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer.
    Schildkraut JM; Bastos E; Berchuck A
    J Natl Cancer Inst; 1997 Jul; 89(13):932-8. PubMed ID: 9214672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The present state of research on the relationship of oral contraceptives to breast cancer].
    Pike MC
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):329-38. PubMed ID: 12280203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early menarche, a risk factor for breast cancer, indicates early onset of ovulatory cycles.
    Apter D; Vihko R
    J Clin Endocrinol Metab; 1983 Jul; 57(1):82-6. PubMed ID: 6222061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Menstrual cycle and exposure to oestrogens unopposed by progesterone: relevance to studies on breast cancer incidence.
    Metcalf MG; Mackenzie JA
    J Endocrinol; 1985 Jan; 104(1):137-41. PubMed ID: 3968497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of moderate physical activity on menstrual cycle patterns in adolescence: implications for breast cancer prevention.
    Bernstein L; Ross RK; Lobo RA; Hanisch R; Krailo MD; Henderson BE
    Br J Cancer; 1987 Jun; 55(6):681-5. PubMed ID: 3620313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endometrial cathepsin D immunostaining throughout ovulatory and anovulatory menstrual cycles.
    Camier B; Hedon B; Rochefort H; Maudelonde T
    Hum Reprod; 1996 Feb; 11(2):392-7. PubMed ID: 8671230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer.
    Key TJ; Pike MC
    Eur J Cancer Clin Oncol; 1988 Jan; 24(1):29-43. PubMed ID: 3276531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urine estrogens, frequency of ovulation, and breast cancer risk: case-control study in premenopausal women.
    MacMahon B; Cole P; Brown JB; Paffenbarger R; Trichopoulos D; Yen S
    J Natl Cancer Inst; 1983 Feb; 70(2):247-50. PubMed ID: 6571932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine response determines the clinical outcome of pulsatile gonadotropin-releasing hormone ovulation induction in different ovulatory disorders.
    Filicori M; Flamigni C; Meriggiola MC; Ferrari P; Michelacci L; Campaniello E; Valdiserri A; Cognigni G
    J Clin Endocrinol Metab; 1991 May; 72(5):965-72. PubMed ID: 1902487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk.
    Pike MC; Spicer DV; Dahmoush L; Press MF
    Epidemiol Rev; 1993; 15(1):17-35. PubMed ID: 8405201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regularity and length of menstrual cycles in women aged 41-46 in relation to breast cancer risk: results from the DOM-project.
    den Tonkelaar I; de Waard F
    Breast Cancer Res Treat; 1996; 38(3):253-8. PubMed ID: 8739077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing of surgery for primary breast cancer with regard to the menstrual phase and prognosis.
    Jatoi I
    Breast Cancer Res Treat; 1998; 52(1-3):217-25. PubMed ID: 10066084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-reproductive Effects of Anovulation: Bone Metabolism in the Luteal Phase of Premenopausal Women Differs between Ovulatory and Anovulatory Cycles.
    Niethammer B; Körner C; Schmidmayr M; Luppa PB; Seifert-Klauss VR
    Geburtshilfe Frauenheilkd; 2015 Dec; 75(12):1250-1257. PubMed ID: 26726266
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.